Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis

[11] Tabas I(2009)Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice Diabetes 58 2574-91

[12] Bornfeldt KE(2010)Macrophage plasticity in experimental atherosclerosis PLoS ONE 5 e8852-322

[13] Tabas I(2016)M1- and M2-type macrophage responses are predictive of adverse outcomes in human atherosclerosis Front Immunol 7 275-1805

[14] Gerhardt T(2016)Inhibition of M1 macrophage activation in adipose tissue by berberine improves insulin resistance Life Sci 166 82-2257

[15] Ley K(2016)Liraglutide and cardiovascular outcomes in type 2 diabetes N Engl J Med 375 311-50

[16] Shalhoub J(2014)Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized crossover trial Diabetes Care. 37 1797-181

[17] Falck-Hansen MA(2015)Lixisenatide in patients with type 2 diabetes and acute coronary syndrome N Engl J Med 373 2247-905

[18] Davies AH(2013)Hölscher C The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain Eur J Pharmacol 700 42-52

[19] Monaco C(2013)The effects of liraglutide on glucose, inflammatory markers and lipoprotein metabolism: current knowledge and future perspective Clin Lipidol 8 173-26

[20] Mosser DM(2017)Liraglutide effects on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: a sub-analysis of a randomised, placebo-controlled, double-blind, cross-over trial Diabetes Obes Metab 19 901-124

[11] Tabas I(2009)Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice Diabetes 58 2574-91

[12] Bornfeldt KE(2010)Macrophage plasticity in experimental atherosclerosis PLoS ONE 5 e8852-322

[13] Tabas I(2016)M1- and M2-type macrophage responses are predictive of adverse outcomes in human atherosclerosis Front Immunol 7 275-1805

[14] Gerhardt T(2016)Inhibition of M1 macrophage activation in adipose tissue by berberine improves insulin resistance Life Sci 166 82-2257

[15] Ley K(2016)Liraglutide and cardiovascular outcomes in type 2 diabetes N Engl J Med 375 311-50

[16] Shalhoub J(2014)Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized crossover trial Diabetes Care. 37 1797-181

[17] Falck-Hansen MA(2015)Lixisenatide in patients with type 2 diabetes and acute coronary syndrome N Engl J Med 373 2247-905

[18] Davies AH(2013)Hölscher C The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain Eur J Pharmacol 700 42-52

[19] Monaco C(2013)The effects of liraglutide on glucose, inflammatory markers and lipoprotein metabolism: current knowledge and future perspective Clin Lipidol 8 173-26

[20] Mosser DM(2017)Liraglutide effects on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: a sub-analysis of a randomised, placebo-controlled, double-blind, cross-over trial Diabetes Obes Metab 19 901-124